DOCSLIB.ORG

Subacute Cutaneous Lupus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subacute Cutaneous Lupus Pearls in Rheumatology- Dermatology Karthik Krishnamurthy, DO Associate Professor Albert Einstein College of Medicine Residency Program Director Orange Park Medical Center Introduction Rheumatologic diseases • Aka connective tissue diseases, collagen vascular diseases • Polygenetic & heterogeneous group of autoimmune disorders with classic cutaneous and extracutaneous findings • Autoantibody associations Conflicts of Interest None Overview Lupus Erythematosus Dermatomyositis Systemic Sclerosis Mixed Connective Tissue Disease Sjögren’s Syndrome Dermatoses associated with arthritis Autoantibodies Circulating immunoglobulins detected in autoimmune diseases Profile contributes to disease phenotype Etiology / inciting event not completely understood Autoantibodies ANA Histone PM-Scl SSA (Ro) RF Centromere SSB (La) Ku Scl-70 dsDNA Mi-2 Calpastatin ssDNA Jo-1 HMG Sm Se Fer U1RNP PCNA Mas U2RNP A-fodrin KJ Th/To RNP PL-7 SRP Cardiolipin PL-12 C1q B2-glycoprotein I OJ/EJ U3RNP (fibrillarin) Antinuclear Antibody (ANA) Screening tool • Good sensitivity (assay-dependent) • Low disease specificity • False positives Antinuclear Antibody (ANA) Assays used to identify ANA • Immunofluorescence – Directed against nuclear antigens on Hep-2 cells (human SCC tumor line) – ↑ # of antigens, ↑ sensitivity, ↑$ • ELISA – Solid phase immunoassay – ↓ # antigens, ↓sensitivity, ↓$ Antinuclear Antibody (ANA) Immunofluorescence staining pattern A: Homogeneous B: Peripheral C: Speckled D: Nucleolar E: Centromeric Bolognia et al. Dermatology. 2007 Antinuclear Antibody (ANA) Mutasim, et al. JAAD Feb 2000 Antinuclear Antibody (ANA) False Positives Mutasim, et al. JAAD Feb 2000 Antinuclear Antibody (ANA) “Normal” ANA cut-off < 1:160 Mutasim, et al. JAAD Feb 2000 Antinuclear Antibody (ANA) Centromere CREST dsDNA Nephritis SSA (Ro) Photosensitivity Vasculitis 90% of La (+) are also Ro (+) 50% of Ro (+) are also La (+) Overview Lupus Erythematosus Dermatomyositis Systemic Sclerosis Mixed Connective Tissue Disease Sjogren’s Syndrome Dermatoses associated with arthritis Lupus Erythematosus (LE) Lupus Erythematosus (LE) Chronic Cutaneous LE Subacute Cutaneous LE Acute (systemic) LE Lupus Erythematosus (LE) Epidemiology • SLE • F:M 6:1 (? Hormonal) • African Americans 4X more likely than whites • CCLE • F:M 3:1 • CCLE → SLE ~ 5-20% Lupus Erythematosus (LE) Pathogenesis • Genetic? • Foreign antigen/molecular mimickry? • Autoantibodies not organ specific Chronic Cutaneous LE CCLE • Classic Discoid LE • Tumid LE • Lupus Panniculitis • Chilblain LE Chronic Cutaneous LE Discoid LE • Face, scalp, ears, with associated alopecia • Less frequently on trunk and ext’s • Mucosa: lips, oral, nasal, genital • No clear association with UV exposure • May have arthralgias Chronic Cutaneous LE Discoid LE • Erythematous papules evolve into scaly plaques • Follicular plugging • Carpet tack / cat-tongue scale • Disfigurement is the worst sequela • Scarring alopecia • Atrophic, hypopigmented plaques • Rarely, SCC may develop in older lesions Discoid LE (CCLE) Discoid LE (CCLE) Langue au chat “Cat’s tongue” Carpet-tack scale Chronic Cutaneous LE • Superficial, deep, interface and periadnexal lymphocytic infiltrates • Epidermal atrophy with/without hyperkeratosis • Follicular plugging • Colloid bodies • Melanin incontinence • May see mucin Escholarship.org Lupus Pernio Rosacea Discoid Lupus Lupus Vulgaris Chronic Cutaneous LE Bolognia, et al. Dermatology (2007) Chronic Cutaneous LE Tumid LE • Erythematous dermal plaques • Lacks scale or follicular plugging • No residual scar or atrophy • Can leave residual dyspigmentation • Head/neck, upper trunk, proximal UE’s • Reproducible with UV exposure • Same / similar to entity Jessner’s Lymphocytic Infiltrate Chronic Cutaneous LE Lupus Panniculitis • Deep, tender, inflammatory nodules occuring at the lever of subcutaneous fat • Heal with scarring and depression of overlying skin (lipoatrophy) • Favors face, UE’s, upper trunk, breast, buttock, thighs • Chronic, remitting and relapsing course • Only 10-15% meet criteria for SLE • If DLE overlies panniculitis, referred to as Lupus Profundus Chronic Cutaneous LE Chilblain LE • Red-purple papules and plaques on acral skin • Fingers, toes, nose, elbows, knees, LE’s • Exacerbated by cold • Chronic • May be differentiated from ordinary chilblains by evolution in discoid lesions both clinically and histologically Chilblain LE Subacute Cutaneous LE SCLE • Classic • Papulosquamous and Annular variants • Neonatal LE • Complement deficiency syndromes • C2 and/or C4 defieciency • Resembles classic SCLE Subacute Cutaneous LE Classic type • Papulosquamous and/or Annular eruption • Predilection for UV-exposed areas • No follicular plugging or scarring • Can leave dyspigmentation • Ro (SSA) antibodies (90% via ELISA) • Many “meet criteria” for SLE • Many cases are drug induced (more later) • Diltiazem (CCB), HCTZ, Terbenafine, NSAIDS, Griseofulvin Subacute Cutaneous LE Subacute Cutaneous LE Neonatal LE • Newborns of (+) Ro, La, or RNP mothers • Erythematous thin scaly plaques • UV sensitive: face/ext’s > trunk • May be present at birth (intrauterine) • May leave residual dyspigmentation or telangiectasia • Usually resolves by 6 months (maternal Ab’s degraded) Subacute Cutaneous LE Neonatal LE • Congenital heart block (3rd degree) • Permanent, 20% mortality • Up to 2/3 require a pacemaker • Hepatobiliary disease • Thrombocytopenia • EKG, CBC, LFT’s, aggressive sun protection • 25% risk with subsequent pregnancies Neonatal LE (SCLE) Neonatal LE (SCLE) Acute Cutaneous LE ACLE • Malar Rash • Discoid Lesions • Diffuse non-scarring alopecia • Raynaud's phenomenon • Nailfold telangiectasias and erythema • Vasculitis • Cutaneous signs of antiphospholipid syndrome: livedo reticularis, acrocyanosis, atrophie blanche • Palmar erythema, dorsal erythema sparing IP joints. • Papular and nodular mucinosis Acute Cutaneous LE SLE Criteria • Discoid Lesions • Oral ulcers • Photosensitivity • (+) ANA • Malar Rash (butterfly rash) • Immunologic markers (dsDNA, Sm) • Neuropsychiatric disturbances • Renal (nephritis) • Arthritis • Serositis • Hematologic (hemolysis, anemia, thrombocytopenia) Malar Rash (ACLE/SLE) Palmer Erythema / Vascular(ACLE/SLE) Special Considerations Bullous SLE • Ab’s to Collagen VII • SLE may occur with other blistering disease Overlap syndromes • Lichen Planus / LE overlap Associations • Erythema Multiforme + SLE = Rowell’s Syndrome • Pemphigus Foliaceus + SLE = Senear-Usher Syndrome Drug-Induced SLE SLE • <30% have skin manifestations • Musculoskeletal and serosal complaints • Procainamide, Hydralazine, Isoniazid, Chlorpromazine, Phenytoin, Methyldopa, Minocycline • Induces anti-Histone Ab’s • Etanercept & d-Penicillamine induce dsDNA ab’s • Methimazole and PTU induce ANCAs (1) Acute Cutaneous Lupus OR Subacute Cutaneous Lupus •Acute cutaneous lupus: lupus malar rash (do not count if malar discoid), bullous lupus, toxic epidermal necrolysis variant of SLE, maculopapular lupus rash, photosensitive lupus rash (in the absence of dermatomyositis) •Subacute cutaneous lupus: nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias) (2) Chronic Cutaneous Lupus •Classic discoid rash localized (above the neck) or generalized (above and below the neck), hypertrophic (verrucous) lupus, lupus panniculitis (profundus), mucosal lupus, lupus erythematosus tumidus, chillblains lupus, discoid lupus/lichen planus overlap (3) Oral Ulcers OR Nasal Ulcers •Oral: palate, buccal, tongue •Nasal ulcers •In the absence of other causes, such as vasculitis, Behcet’s disease, infection (herpesvirus), inflammatory bowel disease, reactive arthritis, and acidic foods (4) Nonscarring alopecia •Diffuse thinning or hair fragility with visible broken hairs, in the absence of other causes such as alopecia areata, drugs, iron deficiency, and androgenic alopecia Dermatomyositis Dermatomyositis DM • Proximal, extensor, symmetric, inflammatory myositis • Photodistributed and classic skin findings • May overlap with other rheumatologic diseases • Adult forms associated with internal malignancy • Amyopathic form exists Dermatomyositis Epidemiology • Adult F:M 6:1 • Juvenile F:M 2:1 Pathogenesis • Genetic, humoral immunity, cellular immunity, drug precipitants, infectious etiology • Paraneoplastic phenomenon Dermatomyositis Skin Findings • Photodistributed poikiloderma (neck, shawl) • Heliotrope rash (periorbital erythema) • Scalp dermatitis • Nailfold telangiectasias • Gottron’s papules: violaceous papules over IP’s • Gottron’s sign: over knees and elbows • Calcinosis cutis (more in juvenile variant) • Mechanic Hands: ragged cuticles, hyperkeratosis, scaling, and fissuring of distal fingers Dermatomyositis Extracutaneous • Proximal muscle weakness • Pulmonary disease – Interstitial lung disease – Anti-tRNA synthetase Ab’s (Jo-1) • Other – If GI, Renal, arthritis, or Raynaud’s, consider overlap – Anti-SRP Ab’s associated with cardiac disease – Anti-Ku Ab’s associated with DM and SSc overlap – Anti-Mi-2 Ab’s associated with shawl sign and good prognosis Dermatomyositis Malignancy Risk • Up to 50% in Adult form • #1: Ovarian Cancer • Less commonly breast, lung, gastric Dermatomyositis Juvenile Variants • Brunsting Type (more common) – Myositis + calcinosis – Indolent, progressive, steroid responsive • Banker Type – Vasculitis of muscles and GI tract – Rapid, difficult to treat, high mortality Dermatomyositis Work-up • Muscle enzymes: CK, aldolase,
Load more

Recommended publications
  • Understanding and Managing Scleroderma
    Understanding and Managing Scleroderma A publication of Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923 Maureen D. Mayes, M.D., M.P.H. Understanding and Understanding My notes and Managing Scleroderma Managing Scleroderma This booklet is intended to help people with scleroderma, their families and others interested ________________________ in learning more about the disease to better understand what scleroderma is, what effects ________________________ it may have, and what those with scleroderma can do to help themselves and their physicians ________________________ manage the disease. It answers some of the most frequently asked questions about ________________________ A publication of Maureen D. Mayes, M.D., M.P.H. Scleroderma Foundation 300 Rosewood Drive, Suite 105 scleroderma. Danvers, MA 01923 800-722-HOPE (4673) www.scleroderma.org www.facebook.com/sclerodermaUS www.twitter.com/scleroderma ________________________ Disclaimer The Scleroderma Foundation does not provide medical advice nor does it ________________________ endorse any drug or treatment mentioned herein. ________________________ The material contained in this booklet is presented for general information only. It is not intended to provide medical advice, to answer questions specific to the condition or problems of particular individuals, nor in ________________________ any way to substitute for the professional advice and care of qualified physicians. Mention of particular drugs and/or treatments is for ________________________ information purposes only and does not constitute an endorsement of said drugs and/or treatments. ________________________ Thanks! ________________________ The Scleroderma Foundation expresses its deep appreciation to the many ________________________ physicians whose efforts have led to this booklet. Special thanks are owed to Maureen D. Mayes, M.D., M.P.H., of the ________________________ University of Texas McGovern Medical School, Houston.
    [Show full text]
  • Dermatological Findings in Common Rheumatologic Diseases in Children
    Available online at www.medicinescience.org Medicine Science ORIGINAL RESEARCH International Medical Journal Medicine Science 2019; ( ): Dermatological findings in common rheumatologic diseases in children 1Melike Kibar Ozturk ORCID:0000-0002-5757-8247 1Ilkin Zindanci ORCID:0000-0003-4354-9899 2Betul Sozeri ORCID:0000-0003-0358-6409 1Umraniye Training and Research Hospital, Department of Dermatology, Istanbul, Turkey. 2Umraniye Training and Research Hospital, Department of Child Rheumatology, Istanbul, Turkey Received 01 November 2018; Accepted 19 November 2018 Available online 21.01.2019 with doi:10.5455/medscience.2018.07.8966 Copyright © 2019 by authors and Medicine Science Publishing Inc. Abstract The aim of this study is to outline the common dermatological findings in pediatric rheumatologic diseases. A total of 45 patients, nineteen with juvenile idiopathic arthritis (JIA), eight with Familial Mediterranean Fever (FMF), six with scleroderma (SSc), seven with systemic lupus erythematosus (SLE), and five with dermatomyositis (DM) were included. Control group for JIA consisted of randomly chosen 19 healthy subjects of the same age and gender. The age, sex, duration of disease, site and type of lesions on skin, nails and scalp and systemic drug use were recorded. χ2 test was used. The most common skin findings in patients with psoriatic JIA were flexural psoriatic lesions, the most common nail findings were periungual desquamation and distal onycholysis, while the most common scalp findings were erythema and scaling. The most common skin finding in patients with oligoarthritis was photosensitivity, while the most common nail finding was periungual erythema, and the most common scalp findings were erythema and scaling. We saw urticarial rash, dermatographism, nail pitting and telogen effluvium in one patient with systemic arthritis; and photosensitivity, livedo reticularis and periungual erythema in another patient with RF-negative polyarthritis.
    [Show full text]
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Urticaria and Prodromal Symptoms Including Erythema Marginatum in Danish Patients with Hereditary Angioedema
    University of Southern Denmark Urticaria and Prodromal Symptoms Including Erythema Marginatum in Danish Patients with Hereditary Angioedema Rasmussen, Eva R; Valente de Freitas, Priscila; Bygum, Anette Published in: Acta Dermatovenereologica DOI: 10.2340/00015555-2233 Publication date: 2016 Document version: Final published version Document license: CC BY Citation for pulished version (APA): Rasmussen, E. R., Valente de Freitas, P., & Bygum, A. (2016). Urticaria and Prodromal Symptoms Including Erythema Marginatum in Danish Patients with Hereditary Angioedema. Acta Dermatovenereologica, 96(3), 373- 376. https://doi.org/10.2340/00015555-2233 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to [email protected] Download date: 07. Oct. 2021 Acta Derm Venereol 2016; 96: 373–376 CLINICAL REPORT Urticaria and Prodromal Symptoms Including Erythema Marginatum in Danish Patients with Hereditary Angioedema Eva Rye RASMUSSEN1,
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Erythema Marginatum
    Figurative Erythemas Michelle Goedken, DO Affiliated Dermatology Scottsdale, AZ Figurative Erythemas • Erythema annulare centrifugum • Erythema marginatum • Erythema migrans • Erythema gyratum repens • Erythema multiforme Erythemas • Erythemas represent a change in the color of the skin that is due to the dilation of blood vessels, especially those in the papillary and reticular dermis • The color is blanchable and most last for days to months • Figurative erythemas have an annular, arciform or polycyclic appearance ERYTHEMA ANNULARE CENTRIFUGUM ERYTHEMA ANNULARE CENTRIFUGUM • Pathogenesis: EAC represents a reaction pattern or hypersensitivity to one of many antigens – IL-2 and TNF-alpha may have a role – Most patients do not have an underlying disease identified ERYTHEMA ANNULARE CENTRIFUGUM • Associated with: – Infection » Dermatophytes and other fungi (Candida and Penicillium in blue cheese) » Viruses: poxvirus, EBV, VZV, HIV » Parasites and ectoparasites – Drugs: diuretics, antimalarials, gold, NSAIDs, finasteride, amitriptyline, etizolam, Ustekinumab (2012) ERYTHEMA ANNULARE CENTRIFUGUM – Foods – Autoimmune endocrinopathies – Neoplasms (lymphomas and leukemias) – Pregnancy – Hypereosinophilic syndrome – Lupus (2014) ERYTHEMA ANNULARE CENTRIFUGUM http://www.dermaamin.com Rongioletti, F., Fausti, V., & Parodi, A ERYTHEMA ANNULARE CENTRIFUGUM • 2 major forms: – Superficial: classic trailing scale, may have associated pruritus – Deep: infiltrated borders, usually no scale, edges are elevated, usually not pruritic ERYTHEMA ANNULARE CENTRIFUGUM
    [Show full text]
  • A Acanthosis Nigricans, 139 Acquired Ichthyosis, 53, 126, 127, 159 Acute
    Index A Anti-EJ, 213, 214, 216 Acanthosis nigricans, 139 Anti-Ferc, 217 Acquired ichthyosis, 53, 126, 127, 159 Antigliadin antibodies, 336 Acute interstitial pneumonia (AIP), 79, 81 Antihistamines, 324 Adenocarcinoma, 115, 116, 151, 173 Anti-histidyl-tRNA-synthetase antibody Adenosine triphosphate (ATP), 229 (Anti-Jo-1), 6, 14, 140, 166, 183, Adhesion molecules, 225–226 213–216 Adrenal gland carcinoma, 115 Anti-histone antibodies (AHA), 174, 217 Age, 30–32, 157–159 Anti-Jo-1 antibody syndrome, 34, 129 Alanine aminotransferase (ALT, ALAT), 16, Anti-Ki-67 antibody, 247 128, 205, 207, 255 Anti-KJ antibodies, 216–217 Alanyl-tRNA synthetase, 216 Anti-KS, 82 Aldolase, 14, 16, 128, 129, 205, 207, 255, 257 Anti-Ku antibodies, 163, 165, 217 Aledronate, 325 Anti-Mas, 217 Algorithm, 256, 259 Anti-Mi-2 Allergic contact dermatitis, 261 antibody syndrome, 11, 129, 215 Alopecia, 62, 199, 290 antibodies, 6, 15, 129, 142, 212 Aluminum hydroxide, 325, 326 Anti-Myo 22/25 antibodies, 217 Alzheimer’s disease-related proteins, 190 Anti-Myosin scintigraphy, 230 Aminoacyl-tRNA synthetases, 151, 166, 182, Antineoplastic agents, 172 212, 215 Antineoplastic medicines, 169 Aminoquinolone antimalarials, 309–310, 323 Antinuclear antibody (ANA), 1, 141, 152, 171, Amyloid, 188–190 172, 174, 213, 217 Amyopathic DM, 6, 9, 29–30, 32–33, 36, 104, Anti-OJ, 213–214, 216 116, 117, 147–153 Anti-p155, 214–215 Amyotrophic lateral sclerosis, 263 Antiphospholipid syndrome (APS), 127, Antisynthetase syndrome, 11, 33–34, 81 130, 219 Anaphylaxi, 316 Anti-PL-7 antibody, 82, 214 Anasarca,
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Eosinophilic Fasciitis (Shulman Syndrome)
    CONTINUING MEDICAL EDUCATION Eosinophilic Fasciitis (Shulman Syndrome) Sueli Carneiro, MD, PhD; Arles Brotas, MD; Fabrício Lamy, MD; Flávia Lisboa, MD; Eduardo Lago, MD; David Azulay, MD; Tulia Cuzzi, MD, PhD; Marcia Ramos-e-Silva, MD, PhD GOAL To understand eosinophilic fasciitis to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Recognize the clinical presentation of eosinophilic fasciitis. 2. Discuss the histologic findings in patients with eosinophilic fasciitis. 3. Differentiate eosinophilic fasciitis from similarly presenting conditions. CME Test on page 215. This article has been peer reviewed and is accredited by the ACCME to provide continuing approved by Michael Fisher, MD, Professor of medical education for physicians. Medicine, Albert Einstein College of Medicine. Albert Einstein College of Medicine designates Review date: March 2005. this educational activity for a maximum of 1 This activity has been planned and implemented category 1 credit toward the AMA Physician’s in accordance with the Essential Areas and Policies Recognition Award. Each physician should of the Accreditation Council for Continuing Medical claim only that credit that he/she actually spent Education through the joint sponsorship of Albert in the activity. Einstein College of Medicine and Quadrant This activity has been planned and produced in HealthCom, Inc. Albert Einstein College of Medicine accordance with ACCME Essentials. Drs. Carneiro, Brotas, Lamy, Lisboa, Lago, Azulay, Cuzzi, and Ramos-e-Silva report no conflict of interest. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. We present a case of eosinophilic fasciitis, or Shulman syndrome apart from all other sclero- Shulman syndrome, in a 35-year-old man and dermiform states.
    [Show full text]
  • Nonvascular Extremity Ultrasound ______
    Comments and Responses Regarding Draft Local Coverage Determination: Nonvascular Extremity Ultrasound _______________________________________________________________________ As an important part of Medicare Local Coverage Determination (LCD) development, National Government Services solicits comments from the provider community and from members of the public who may be affected by or interested in our LCDs. The purpose of the advice and comment process is to gain the expertise and experience of those commenting. We would like to thank those who suggested changes to the Nonvascular Extremity Ultrasound LCD . The official notice period for the final LCD begins on April 15, 2009, and the final determination will become effective on July 1, 2009. Comment: A physician from the Indiana Carrier Advisory Committee (CAC) suggested to include the following ICD-9-CM codes: 729.5 – Other disorders of soft tissues, pain in limb; 782.2 – Symptoms involving skin and other integumentary tissue localized superficial swelling, mass, or lump. There are times when the localized superficial code is more appropriately used. Response: The contractor agrees that these diagnoses are consistent with indications in the LCD and the suggested ICD-9-CM codes will be added. _______________________________________________________________________ Comment: A podiatrist suggested adding the following to the “LIMITATIONS” section of the LCD: Neuromas, plantar fasciitis, superficial ganglia, bursae and abscesses unless there is documented evidence of some clinical presentation that obscures the clinician's ability to establish these simple clinical diagnoses. In the case of plantar fasciitis, diagnostic ultrasound is NOT to be used in making an initial determination (diagnosis) and then should ONLY be used after a failed course of conservative management.
    [Show full text]
  • Hot in the Tropics
    CLINICAL CARE CONUNDRUMS Hot in the Tropics The approach to clinical conundrums by an expert clinician is revealed through the presentation of an actual patient’s case in an approach typical of a morning report. Similarly to patient care, sequential pieces of information are provided to the clinician, who is unfamiliar with the case. The focus is on the thought processes of both the clinical team caring for the patient and the discussant. This icon represents the patient’s case. Each paragraph that follows represents the discussant’s thoughts Arpana R. Vidyarthi, MD1,2*, Gurpreet Dhaliwal, MD3,4, Bradley Monash, MD3, Koin Lon Shum, MD5, Joanne Lee, MBBS6, Aimee K. Zaas, MD, MHS7 1Duke-NUS Graduate Medical School, Singapore; 2Department of Medicine, National University Health System, Singapore; 3Department of Medi- cine, University of California, San Francisco, California; 4Medical Service, San Francisco VA Medical Center, San Francisco, California; 5Department of Internal Medicine, Singapore General Hospital, Singapore; 6Department of Haematology-Oncology, National University Cancer Institute, Singapore; 7Department of Medicine, Duke University School of Medicine, Durham, North Carolina. A 42-year-old Malaysian construction worker with 207,000/μL. Serum chemistries were normal. C-reactive subjective fevers of 4 days’ duration presented to an protein (CRP) level was 44.6 mg/L (reference range, 0.2- emergency department in Singapore. He reported nonpro- 9.1 mg/L), and procalcitonin level was 0.13 ng/mL (refer- ductive cough, chills without rigors, sore throat, and body ence range, <0.50 ng/mL). Chest radiograph was normal. aches. He denied sick contacts. Past medical history in- Dengue antibodies (immunoglobulin M, immunoglobulin G cluded chronic hepatitis B virus (HBV) infection.
    [Show full text]
  • Dermatological Indications of Disease - Part II This Patient on Dialysis Is Showing: A
    “Cutaneous Manifestations of Disease” ACOI - Las Vegas FR Darrow, DO, MACOI Burrell College of Osteopathic Medicine This 56 year old man has a history of headaches, jaw claudication and recent onset of blindness in his left eye. Sed rate is 110. He has: A. Ergot poisoning. B. Cholesterol emboli. C. Temporal arteritis. D. Scleroderma. E. Mucormycosis. Varicella associated. GCA complex = Cranial arteritis; Aortic arch syndrome; Fever/wasting syndrome (FUO); Polymyalgia rheumatica. This patient missed his vaccine due at age: A. 45 B. 50 C. 55 D. 60 E. 65 He must see a (an): A. neurologist. B. opthalmologist. C. cardiologist. D. gastroenterologist. E. surgeon. Medscape This 60 y/o male patient would most likely have which of the following as a pathogen? A. Pseudomonas B. Group B streptococcus* C. Listeria D. Pneumococcus E. Staphylococcus epidermidis This skin condition, erysipelas, may rarely lead to septicemia, thrombophlebitis, septic arthritis, osteomyelitis, and endocarditis. Involves the lymphatics with scarring and chronic lymphedema. *more likely pyogenes/beta hemolytic Streptococcus This patient is susceptible to: A. psoriasis. B. rheumatic fever. C. vasculitis. D. Celiac disease E. membranoproliferative glomerulonephritis. Also susceptible to PSGN and scarlet fever and reactive arthritis. Culture if MRSA suspected. This patient has antithyroid antibodies. This is: • A. alopecia areata. • B. psoriasis. • C. tinea. • D. lichen planus. • E. syphilis. Search for Hashimoto’s or Addison’s or other B8, Q2, Q3, DRB1, DR3, DR4, DR8 diseases. This patient who works in the electronics industry presents with paresthesias, abdominal pain, fingernail changes, and the below findings. He may well have poisoning from : A. lead. B.
    [Show full text]